228 related articles for article (PubMed ID: 19209537)
1. [Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group].
Greco MT; Deandrea S; Corli O; Montanari M; Caraceni A; Apolone G;
Recenti Prog Med; 2008 Nov; 99(11):538-51. PubMed ID: 19209537
[TBL] [Abstract][Full Text] [Related]
2. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.
Apolone G; Corli O; Negri E; Mangano S; Montanari M; Greco MT; ; Apolone G; Bertetto O; Caraceni A; Corli O; De Conno F; Labianca R; Maltoni M; Nicora Maria F; Torri V; Zucco F
Clin J Pain; 2009 Oct; 25(8):671-82. PubMed ID: 19920716
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
Griessinger N; Sittl R; Likar R
Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
[TBL] [Abstract][Full Text] [Related]
5. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.
Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O;
Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402
[TBL] [Abstract][Full Text] [Related]
6. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
[TBL] [Abstract][Full Text] [Related]
7. Transdermal buprenorphine in cancer pain and palliative care.
Sittl R
Palliat Med; 2006; 20 Suppl 1():s25-30. PubMed ID: 16764218
[TBL] [Abstract][Full Text] [Related]
8. [Post marketing surveillance study with an analgesic (transdermal buprenorphine patch) in patients with moderate to severe chronic pain].
Tschirner M; Ritzdorf I; Brünjes R
MMW Fortschr Med; 2008 Sep; 150 Suppl 3():142-8. PubMed ID: 19025217
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain.
Poulain P; Denier W; Douma J; Hoerauf K; Samija M; Sopata M; Wolfram G
J Pain Symptom Manage; 2008 Aug; 36(2):117-25. PubMed ID: 18411010
[TBL] [Abstract][Full Text] [Related]
10. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
11. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine TDS: use in daily practice, benefits for patients.
Radbruch L
Int J Clin Pract Suppl; 2003 Feb; (133):19-22; discussion 23-4. PubMed ID: 12665120
[TBL] [Abstract][Full Text] [Related]
14. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies.
Penza P; Campanella A; Martini A; Melli G; Lombardi R; Camozzi F; Devigili G; Lauria G
J Peripher Nerv Syst; 2008 Dec; 13(4):283-8. PubMed ID: 19192068
[TBL] [Abstract][Full Text] [Related]
15. High dose transdermal buprenorphine for moderate to severe pain in spanish pain centres--a retrospective multicenter safety and efficacy study.
Barutell C; Camba A; González-Escalada JR; Rodríguez M;
Pain Pract; 2008; 8(5):355-61. PubMed ID: 18662364
[TBL] [Abstract][Full Text] [Related]
16. Buprenorphine TDS: the clinical development rationale and results.
Radbruch L; Vielvoye-Kerkmeer A
Int J Clin Pract Suppl; 2003 Feb; (133):15-8; discussion 23-4. PubMed ID: 12665119
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of chronic osteoarthritis pain: effectivity and safety of a 7 day matrix patch with a low dose buprenorphine].
Schutter U; Ritzdorf I; Heckes B
MMW Fortschr Med; 2008 Jun; 150 Suppl 2():96-103. PubMed ID: 18712130
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
19. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age.
Likar R; Vadlau EM; Breschan C; Kager I; Korak-Leiter M; Ziervogel G
Clin J Pain; 2008; 24(6):536-43. PubMed ID: 18574363
[TBL] [Abstract][Full Text] [Related]
20. Intravenous naloxone plus transdermal buprenorphine in cancer pain associated with intractable cholestatic pruritus.
Marinangeli F; Guetti C; Angeletti C; Bonetti C; Paladini A; Piroli A; Varrassi G
J Pain Symptom Manage; 2009 Oct; 38(4):e5-8. PubMed ID: 19699606
[No Abstract] [Full Text] [Related]
[Next] [New Search]
